Interview: The metabolic route to drug discovery Interviewee/Contributor David Moller Organisation Poxel SA Drug discovery Strategy Diabetes Read more about Interview: The metabolic route to drug discovery
Interview: Targeting diseases of cortisol deficiency Interviewee/Contributor Martin Whitaker Organisation Diurnal Group Plc Drug discovery Strategy Read more about Interview: Targeting diseases of cortisol deficiency
The changing landscape for haemophilia treatment Interviewee/Contributor Victoria English Organisation MedNous Drug discovery Gene therapy Read more about The changing landscape for haemophilia treatment
Hope rekindled for Alzheimer's disease treatment Interviewee/Contributor Andrea Pfeifer Organisation AC Immune SA Drug discovery Read more about Hope rekindled for Alzheimer's disease treatment
Genetic risk assessment in Alzheimer's disease Interviewee/Contributor Alex Gibson Organisation Cytox Ltd Biomarker Read more about Genetic risk assessment in Alzheimer's disease
Time for action against antimicrobial resistance Interviewee/Contributor Lars Rebien Sørensen Organisation Novo Nordisk Foundation Commentary Antibiotics drug-resistant pathogens Read more about Time for action against antimicrobial resistance
Why we all go to JP Morgan year after year Interviewee/Contributor Edwin Moses Organisation Achilles Therapeutics Ltd Commentary Read more about Why we all go to JP Morgan year after year
Discovery suggests new approach to liver disease Interviewee/Contributor Peter Charlish Organisation MedNous Academic Research Drug discovery Cancer - liver Read more about Discovery suggests new approach to liver disease
New treatments for macular degeneration Interviewee/Contributor Peter Charlish Organisation MedNous Drug discovery Strategy Read more about New treatments for macular degeneration
The US continues to lead in oncology approvals Interviewee/Contributor Bruno Pagliara Organisation MedNous Antibody Drug Conjugates ADCs Cancer (Oncology) Clinical trials Immunotherapy Policy & Regulation Read more about The US continues to lead in oncology approvals